Introduction
The prevalence of heart failure (HF) has exponentially increased over the last decades and it has been estimated that it will grow further, reaching up to 10% of the general population in 2030.
1 HF is associated with high mortality rates, up to 50% at 5 years and over 70% at 10 years from its first diagnosis. 
optimal clinical management. However, even currently established biomarkers present some limitations, 2 in particular they do not allow an aetiology-based diagnosis.
MicroRNAs (miRNAs) are short, non-coding RNAs that modulate gene expression at a post-transcriptional level, through sequence-specific binding of target messenger RNAs. They are deeply involved in the development of the cardiovascular system and in the pathophysiology of cardiovascular diseases. 3, 4 Moreover, they can be detected in the circulating blood. 5, 6 Since circulating miRNAs are seemingly quite stable, they may be exploited as blood-borne biomarkers. 5 In fact, several studies reported an association between circulating levels of specific miRNAs and cardiovascular diseases, including acute myocardial infarction, 5, 6 myocarditis, 7 takotsubo syndrome, 8 acute and chronic HF, 9 stable coronary artery disease, 10, 11 in-stent restenosis, 3, 11, 12 type 2 diabetes, 13 or in association with different levels of platelet activity.
14 Importantly, since specific miRNAs are differentially expressed in different cell types, circulating levels of specific miRNAs might reflect different biological alterations, which could provide useful hints to the underlying aetiopathogenesis. 15 In this context, we evaluated the transcoronary expression gradients of selected circulating miRNAs in HF patients, to investigate whether a specific release from the heart could be found for different aetiologies underlying HF.
Methods

Study sample
A total of 75 subjects undergoing coronary angiography at the catheterization laboratories of the Federico II University of Naples (Italy) were enrolled. Patients were classified into three groups according to their clinical status as follows: (i) patients with no evidence of cardiovascular disease undergoing percutaneous closure of a patent foramen ovale (control group); (ii) patients with HF with an underlying ischaemic cardiomyopathy (ICM) undergoing cardiac catheterization for implantation of an implantable cardioverter defibrillator (ICD); (iii) patients with HF but no underlying ischaemic cardiomyopathy (NICM) undergoing cardiac catheterization for ICD implantation.
Exclusion criteria were a known history of leucopenia, thrombocytopenia, or severe hepatic or renal dysfunction, as well as ongoing inflammatory or malignant disease. In addition, diagnosis of myocarditis or the presence of cardiogenic shock were also exclusion criteria.
On the basis of the expected expression values of miR-423 and its standard deviation, we calculated that 60 patients would have been required to have an 80% chance of detecting a two-fold increase in miRNA expression levels between the ICM-HF and NICM-HF groups (primary study outcome), at a significance level of 0.05. However, the total number of HF patients included was raised to 64 to account for asymmetrical distribution (consecutive inclusion independent of the aetiological group) and eventual technical issues with detection of miRNAs in some samples. Patients undergoing cardiac catheterization for percutaneous occlusion of a patent foramen ovale with no evidence of cardiac impairment during the enrolment period were also included to serve as a control group.
The ethics review board of the Magna Graecia University of Catanzaro approved the protocols, and the study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each participant.
Blood collection and storage
Blood samples were simultaneously obtained from the coronary venous sinus (CVS) and the aortic bulb during the cardiac catheterization procedure, before heparin or any contrast agent was administered and before starting any interventional procedure. After centrifugation,
samples were transferred to RNase/DNase-free tubes and stored at −80 ∘ C.
RNA preparation
Total RNA in plasma was isolated by using TRI Reagent BD following the instructions from the manufacturer with modifications. To date, no housekeeping miRNA has been established and validated to normalize for the miRNA content. Therefore, we supplemented the samples (after addition of TRIzol LS) with 5 nmol/L Caenorhabditis elegans miR-39 (cel-miR-39), as described previously.
10
Real-time quantitative reverse transcriptase-polymerase chain reaction analysis RNA was obtained as outlined above and diluted 1:10. Diluted RNA (5 L) was reverse transcribed using the TaqMan miRNA Reverse Transcription kit (ABI) according to the instructions of the manufacturer. Subsequently, 3 L of the product was used for detecting miRNA expression by quantitative polymerase chain reaction using TaqMan miRNA Assay kits (ABI) for the corresponding miRs. cel-miR-39 was added as a spike-in control. In addition to cel-miR-39, miR-1249 was also tested as an endogenous alternative for sample normalization, as previously described. 10 However, cel-miR-39 was preferred, for its lower degree of variation between the samples. Reactions were run in triplicate, and the mean value was used for all analyses, to limit variability associated with methodological reasons. MiRNA levels are expressed as 2-ΔCT [miRNA -cel-miR-39]. Transcoronary concentration gradients were calculated as the ratio between miRNA levels measured in the CVS and those measured in the aorta.
Statistical analysis
The quantitative data were analysed by means of the Kruskal-Wallis, Mann-Whitney U test, or Wilcoxon test (paired sample), as specified in the figure legends. For categorical variables, the Fisher's exact test or the 2 test were used. Pearson correlation was used to compare miRNA levels with other factors.
All P-values are two-sided and less than 0.05 was considered a statistically significant difference. All statistical calculations were performed using IBM SPSS Statistics 23.0 for Windows.
Results
Study sample
A total of 75 subjects were included. Eleven control subjects undergoing percutaneous closure of patent foramen ovale with no further structural heart anomalies and normal cardiac function, 41 patients with ICM-HF, and 23 patients with NICM-HF undergoing consecutively cardiac catheterization were enrolled. The clinical characteristics of the study groups are summarized in Table 1 . Overall, HF patients presented a markedly reduced left ventricular function [left ventricular ejection fraction (LVEF) 29.7 ± 6.8%] and substantially increased plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (2944 ± 5671 pg/mL). Accordingly, 32% of these patients were in New York Heart Association ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CCB, calcium channel blocker; EDD, end-diastolic diameter; ESD, end-systolic diameter; HDL, high-density lipoprotein; HF, heart failure; ICM-HF, ischaemic heart failure; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; NICM-HF, non-ischaemic heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
class III or IV. As reported in Table 1 , HF patients were on optimal medical treatment, with 68% of them on beta-blockers, 45% on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 45% on potassium-sparing diuretics. As compared to HF groups, control patients were younger, had normal left ventricular dimensions and function, no elevation in NT-proBNP levels, and were not taking cardiovascular drugs, except for acetylsalicylic acid in 64% of cases.
MicroRNA selection process
The selection process of specific miRNAs to be measured was performed by means of a systematic review of previously published studies. A detailed description is available in the Supplementary material online, Appendix S1. Briefly, we performed a systematic literature search with selection of 102 articles ( Figure 1 ). From these, the following miRNAs were selected for biological plausibility among those appearing more frequently: miR-423, miR-34a, . . This panel of miRNAs was initially screened in a randomly selected subpopulation of 18 patient samples. Of these miRNAs, miR-208 and miR-133 were unmeasurable in the majority of samples and were therefore excluded from any further analysis. Figure 2 displays the magnitude of the modulation of the remaining seven miRNAs for NICM-HF and ICM-HF patients, expressed as fold-change between the levels measured in the CVS of HF patients and those measured in the CVS of control patients. The miRNAs showing a fold-change ≥5 in at least one of the two HF groups were subsequently assessed. P < 0.001) only in ICM-HF patients, whereas no substantial differences were observed in the NICM-HF group ( Figure 3A) . Similarly, concentrations of miR-34a presented a similar increase in both the aorta (6.6-fold, P = 0.011) and the CVS (16.5-fold, P < 0.001) of ICM-HF patients ( Figure 3A) .
On the other hand, levels of miR-21-3p were significantly increased in both the aorta (4.5-fold, P = 0.003) and the CVS (11.9-fold, P < 0.001) of NICM-HF patients, as compared to the control group. In contrast, no significant increase was observed in ICM-HF patients ( Figure 3B) . On the contrary, plasma levels of miR-126 were substantially reduced both in the aorta (23.3-fold, P < 0.001) and the CVS (7.8-fold, P < 0.001) of ICM-HF patients. A similar modulation was observed in the aorta (31.2-fold, P < 0.001) and the CVS (29.3-fold, P < 0.001) of NICM-HF patients ( Figure 3B) .
In addition, plasma levels of miR-199 were significantly higher in the aorta (4.6-fold, P = 0.040) and the CVS (4.8-fold, P = 0.027) of ICM-HF patients. A larger modulation was observed in the aorta (15.4-fold, P < 0.001) and the CVS (17.2-fold, P < 0.001) of NICM-HF patients ( Figure 3C) were not significantly higher in the aorta (P = 0.756) and the CVS (P = 0.104) of ICM-HF patients. On the contrary, a significant increase was observed in the CVS (15.8-fold, P < 0.001), but not in the aorta (P = 0.163) of NICM-HF patients ( Figure 3C ).
Transcoronary concentration gradients
In order to test whether the modulation in the levels of circulating miRNAs observed in HF patients were heart-specific, miRNA levels were measured in blood samples obtained from the aorta and CVS. 6 Transcoronary concentration gradients were calculated as the ratio between miRNA levels measured in the CVS and those measured in the aorta ( Figure 4) .
As shown in Figure 5A , there was a positive transcoronary concentration gradient for miR-423 only in ICM-HF patients (P = 0.006), but not in NICM-HF patients (P = 0.951), suggesting its selective release into the coronary circulation in this aetiological HF group. Accordingly, a significant transcoronary gradient was confirmed at Wilcoxon rank test in the ICM-HF group (P < 0.001), but not in controls (P = 0.155) or NICM-HF patients (P = 0.296). Similarly, a more modest, though significant, positive transcoronary concentration gradient was found for the circulating levels of miR-34a ( Figure 5B ) in the ICM-HF group (P < 0.001). Accordingly, a significant transcoronary gradient was confirmed at Wilcoxon rank test in the ICM-HF group (P < 0.001), but not in controls (P = 0.646) or NICM-HF patients (P = 0.177).
In contrast, a positive transcoronary concentration gradient for miR-21-3p was found only in NICM-HF patients (P = 0.036), suggesting its selective release into the coronary circulation in this aetiological HF group ( Figure 5C ). In fact, no gradient was documented in the ICM-HF group (P = 0.798). Accordingly, a significant transcoronary gradient was confirmed at Wilcoxon rank test in the NICM-HF group (P < 0.001), but not in controls (P = 0.600) or ICM-HF patients (P = 0.198).
The transcoronary concentration gradient of circulating miR-126 presented no significant variation in both ICM-HF (P = 0.611) and NICM-HF patients (P = 0.749) compared to the control group ( Figure 5D) .
Despite the differential expression documented for miR-199 between the three patient groups, no significant transcoronary concentration gradient was found in any of the groups ( Figure 5E) .
Finally, the transcoronary concentration gradient of miR-30a showed no significant variation in ICM-HF patients (P = 0.763) but a significant transcoronary gradient was detected in NICM-HF patients (P = 0.030) compared to the control group ( Figure 5F) Importantly, treatment with calcium channel blockers had a significant impact on the transcoronary concentration gradient of miR-423 (r = 0.423; P = 0.002) and miR-126 (r = 0.546; P < 0.001), while ongoing treatment with angiotensin receptor blockers was significantly associated with the aortic concentration of miR-423 (r = 0.294; P = 0.032).
Correlation between circulating microRNA concentration and prognostic parameters
In order to further document an association between circulating concentrations of miRNAs and clinical parameters known to be associated with long-term prognosis in HF patients, we correlated individual miRNA levels with known prognostic predictors 16 -18 and found that the CVS concentration of miR-34a was significantly correlated with haemodynamic parameters, such as systolic blood pressure (r = 0.289; P = 0.025), diastolic blood pressure (r = 0.258; P = 0.047), and heart rate (r = 0.349; P = 0.006), as well as with triglyceridaemia (r = 0.364; P = 0.027). Finally, the transcoronary gradient of miR-34a was correlated with heart rate (r = 0.597; P < 0.001) and age (r = 0.253; P = 0.041).
Moreover, the CVS plasma concentration of miR-126 was also significantly associated with LVEF (r = 0.444; P < 0.001) and diastolic left ventricular function, expressed as the E/A ratio (r = 0.454; P = 0.039). A similar correlation was found between the aortic levels of miR-126 and LVEF (r = 0.403; P = 0.002) or the E/A ratio Figure 3 Circulating microRNA levels in coronary sinus and aortic blood. Levels of miR-423 and miR-34a (A), miR-21-3p and miR-126 (B), and miR-199 and miR-30a (C) measured in coronary sinus (gray, left) and aortic blood (black, right) in the three patient groups. Between-group comparisons were performed using the Mann-Whitney U test. HF, heart failure; ICM-HF, ischaemic heart failure; NICM-HF, non-ischaemic heart failure. (r = 0.407; P = 0.060). In addition, CVS levels of miR-126 were also correlated with gender (r = -0.277; P = 0.020), while aortic levels of miR-126 were correlated with total cholesterol (r = 0.335; P = 0.046) and low-density lipoprotein cholesterol (r = 0.407; P = 0.021). Finally, CVS levels of miR-21-3p were significantly correlated with both end-diastolic diameter (r = 0.333; P = 0.029) and end-systolic diameter (r = 0.383; P = 0.011). Transcoronary concentration gradients of miR-21-3p were significantly correlated with end-diastolic diameter (r = 0.554; P < 0.001) and end-systolic diameter (r = 0.604; P < 0.001) (Table 2 and Figure 6 ).
Peripheral venous blood samples from the antecubital vein were available from a subpopulation of 18 patients. Correlation between miRNA levels measured in peripheral blood samples and those measured in the aorta or CVS are reported in Table 3 . In particular, peripheral blood levels of miR-21-3p were significantly correlated with those measured in the CVS (r = 0.398; P = 0.024); peripheral blood levels of the miR-34a were significantly correlated with those measured in the aorta (r = 0.425; P = 0.030); peripheral blood levels of miR-126 were significantly correlated with those measured in the aorta (r = -0.375; P = 0.029) and the CVS (r = -0.382; P = 0.026).
Discussion
The results of the present study show for the first time aetiology-specific transcoronary concentration gradients of circulating miRNAs in HF patients. In particular, while circulating levels of miR-423 and miR-34a were higher in HF patients, particularly in the ICM-HF group, compared to the control group, expression . levels of miR-21-3p, miR-199 and miR-30a were dramatically more elevated in the NICM-HF group. On the contrary, circulating levels of miR-126 were reduced in both HF groups. These results suggest that the circulating levels of specific miRNAs reflect at least in part specific pathophysiological processes underlying HF in different aetiological groups. Moreover, the differential modulation of circulating miRNAs during the transcoronary passage further supports this hypothesis and most probably reflects cell type-specific expression levels and release mechanisms associated with myocardial remodelling in patients with HF. Several studies reported the involvement of miRNAs in various pathogenic mechanisms underlying HF, such as remodelling, hypertrophy, apoptosis, and hypoxia.
19,20 Importantly, a dynamic modulation of miRNAs was reported across different disease stages, or in association with specific aetiologies of HF, 20 with obvious implications for their prognostic potential.
These results, together with previous evidence, pave the way to the use of miRNAs as disease biomarkers in HF patients. To this regard, our finding of a correlation between peripheral and central blood samples, at least for some of the selected miRNAs, demonstrates that changes in their peripheral venous blood levels reflect the variation of their peri-myocardial concentration, which makes them potentially useful as HF biomarkers in the clinical setting. Prospective clinical endpoint studies are needed to test their actual usefulness.
Among the most investigated circulating miRNAs in HF, miR-423 was first proposed as a disease biomarker by Tijsen et al. 9 reporting a promising discriminatory ability to identify HF-associated dyspnoea from dyspnoea of different origins. In line with these results, Figure 5 Transcoronary concentration gradients of circulating microRNAs: transcoronary concentration gradients, expressed as the ratio between their expression levels in the coronary venous sinus and the aorta (CVS/Ao) for miR-423 (A), miR-34a (B), miR-21-3p (C), miR-126 (D), miR-199 (E) and miR-30a (F). Between-group comparisons were performed using the Mann-Whitney U test. ICM-HF, ischaemic heart failure; NICM-HF, non-ischaemic heart failure.
Goren et al. 21 evaluated the expression levels of 186 circulating miRNAs in blood samples from 30 HF patients and reported a 1.5-fold increase of miR-423 levels compared to healthy volunteers. In this context, Goldraich et al. 22 reported a modest but statistically significant transcoronary concentration gradient of miR-423 in 16 patients with HF of different aetiologies, despite no difference was observed in the levels of miR-423 in venous, arterial or coronary sinus samples between HF patients and controls. Although these conflicting results raised some concern and several debates around this research topic, 23, 24 they kept the spotlights on miR-423. Among the more recent reports, Seronde et al. 25 found that lower levels of circulating miR-423 are associated with a poorer prognosis in patients with acute HF, while Kuosmanen et al. 26 differences reported were not statistically significant, most probably due to the small sample size. Several reasons were suggested to explain the large discrepancies reported about the circulating levels of miR-423 and their clinical significance in HF patients. In fact, most studies had small sample sizes, often used heterogeneous diagnostic criteria, and grouped different pharmacological treatments across different disease stages. 23 Most importantly, patients were evaluated independently of HF aetiology and/or treatment received before and/or during the study. In fact, around half of all HF patients included in the studies by Goren et al. 21 and Tijsen et al. 9 had an ischaemic/atherosclerotic aetiology but the limited sample size did not allow to check for inter-group differences. Hence, the modulation in the expression levels of miR-423 could have been driven by the higher levels found in the ICM-HF group. On the other hand, no specific aetiology groups were reported in the study by Goren and colleagues.
On the contrary, in the present study we looked into different aetiology groups and indeed found that multiple circulating miRNAs are differently regulated between ischaemic and non-ischaemic HF patients. Our results are in line with previous findings by Kousmanen et al. 26 reporting different levels of miR-423 in the pericardial fluid, depending on the specific aetiology underlying HF. In addition, our finding that miR-423 levels in ICM-HF are significantly higher than in NICM-HF is in line with the observation of higher miR-423 levels in patients with unstable angina. 27 Moreover, our finding of a transcoronary concentration gradient of . miR-423 in one specific aetiology group further suggests that the modulation of its expression levels reflects the pathophysiological background of HF. Although the biological function of miR-423 is still unknown, it is known that its levels are up-regulated in the failing myocardium. 28 This evidence, together with the demonstration of a transcoronary gradient, suggests that increased circulating levels are related to the up-regulation in the myocardium. Different cell types express miR-423, however higher levels have been reported in cardiomyocytes compared to fibroblasts. 27 In addition, the different regulation of the circulating miRNAs selected for the present analysis across different HF groups represents a potential added value for their clinical use as biomarkers. In fact, if positive transcoronary gradients were found for miR-423 and miR-34a in ischaemic HF, patients with non-ischaemic HF presented a positive concentration gradient for miR-21-3p. On the other hand, the circulating levels of miR-126 were decreased in both HF groups compared to the control group. Thus, if confirmed in large prospective validation studies, the combined measurement of these miRNAs could be very helpful for the etiological diagnosis of HF. The finding of a modulation in the levels of these specific miRNAs is particularly interesting, since they are all involved in the pathophysiology of left ventricular dysfunction. In particular, miR-34a had been previously associated with left ventricular remodelling and clinical prognosis, 29 and a modest increase in its levels was reported in HF patients. 30 In line with those preliminary observations, we found that miR-34a levels are indeed increased in HF, with a positive transcoronary concentration gradient, particularly in the ICM-HF subgroup, which was significantly correlated with haemodynamic parameters, such as heart rate and blood pressure. Moreover, the previous finding that identified FOXO3a as a direct target of miR-34a 31 increases the interest of our findings, as FOXO3a is deeply involved in the modulation of apoptosis and myocardial cell loss and ventricular dysfunction in HF. 31, 32 Hence, miR-34a could be exploited both for aetiological diagnosis of HF and as a potential therapeutic target in treatment strategies aiming at reducing chronic myocardial damage in HF patients. A modulation in the expression levels of both miR-21-5p and miR-21-3p had been previously reported. However, the latter was more interesting as it is involved in the pathophysiology of HF and left ventricular hypertrophy, and . it mediates cell-to-cell communications between fibroblasts and cardiomyocytes. 33 To this regard, in the present study, CVS levels of miR-21-3p were significantly correlated with multiple parameters of left ventricular function, such as LVEF, end-diastolic and end-systolic diameters. Also in line with our findings, lower circulating levels of miR-126 had been reported in HF patients, where its levels were correlated with age, left ventricular function, NT-proBNP levels, and left atrial volume. 34 Interestingly, circulating levels of miR-126 were shown to correlate with the cardiac repair potential. 30 Similarly, miR-126 levels were significantly correlated with age, gender, cholesterol levels, and left ventricular function.
Measured concentrations of circulating miRNAs may be affected by multiple parameters, including tissue expression, sample processing and storage, the release by specific cells into the circulation and their stability. In addition, the binding with plasma proteins or complex macromolecular complexes, as well as their packaging in microvesicles or circulating exosomes, also potentially affect measured levels of circulating miRNAs. All these factors may have contributed to the inter-individual variance in the measured miRNA levels. However, the limited sample size did not allow to test for those factors in the present study.
In summary, circulating concentrations of selected miRNAs are significantly modified upon passage through the coronary circulation. Most interesting, individual miRNAs present a specific transcoronary concentration gradient in different aetiological patient groups, suggesting their potential utility to discriminate between different aetiologies underlying HF. Future studies will have to address whether the aetiology-specific transcoronary circulation gradient of miRNAs are reflected in different peripheral blood concentrations to verify their actual clinical utility in HF.
